Renaissance Technologies LLC Has $255,000 Position in Neuronetics, Inc. (NASDAQ:STIM)

Renaissance Technologies LLC cut its holdings in Neuronetics, Inc. (NASDAQ:STIM) by 72.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 158,600 shares of the company’s stock after selling 423,200 shares during the period. Renaissance Technologies LLC owned 0.52% of Neuronetics worth $255,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Tradewinds LLC. acquired a new position in Neuronetics during the 4th quarter valued at $32,000. David J Yvars Group increased its stake in Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares during the period. JPMorgan Chase & Co. increased its position in shares of Neuronetics by 10,954.1% during the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after purchasing an additional 54,442 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after acquiring an additional 8,466 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Stephen Furlong sold 10,845 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total transaction of $41,536.35. Following the sale, the chief financial officer now directly owns 471,727 shares of the company’s stock, valued at $1,806,714.41. This represents a 2.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP William Andrew Macan sold 12,175 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total transaction of $46,630.25. Following the completion of the sale, the executive vice president now directly owns 388,647 shares of the company’s stock, valued at approximately $1,488,518.01. This represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 100,369 shares of company stock valued at $358,929 in the last 90 days. 8.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group increased their target price on Neuronetics from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th.

Neuronetics Price Performance

Shares of STIM stock opened at $4.50 on Tuesday. Neuronetics, Inc. has a 52 week low of $0.52 and a 52 week high of $5.92. The stock has a market capitalization of $296.17 million, a PE ratio of -3.66 and a beta of 1.92. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16. The stock’s fifty day moving average is $4.25 and its 200-day moving average is $2.75.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.